Nafziger AN - Search Results

1

Miller BV, Bertino JS, Reed RG, Burrington CM, Davidson LK, Green A, Gartung AM, Nafziger AN. Miller BV, et al. Among authors: nafziger an. Metab Syndr Relat Disord. 2003 Dec;1(4):299-309. doi: 10.1089/1540419031361426. Metab Syndr Relat Disord. 2003. PMID: 18370655

2

The effect of oral pleconaril on hepatic cytochrome P450 3A activity in healthy adults using intravenous midazolam as a probe.

Ma JD, Nafziger AN, Rhodes G, Liu S, Gartung AM, Bertino JS Jr. Ma JD, et al. Among authors: nafziger an. J Clin Pharmacol. 2006 Jan;46(1):103-8. doi: 10.1177/0091270005283286. J Clin Pharmacol. 2006. PMID: 16397289 Clinical Trial.

3

Pharmacodynamics of uniform versus nonuniform warfarin dosages.

Hameed MS, Nafziger AN, Gartung AM, Bertino JS Jr. Hameed MS, et al. Among authors: nafziger an. Pharmacotherapy. 2008 Jun;28(6):707-11. doi: 10.1592/phco.28.6.707. Pharmacotherapy. 2008. PMID: 18503398 Clinical Trial.

4

Evaluation of inhibitory drug interactions during drug development: genetic polymorphisms must be considered.

Lee LS, Nafziger AN, Bertino JS Jr. Lee LS, et al. Among authors: nafziger an. Clin Pharmacol Ther. 2005 Jul;78(1):1-6. doi: 10.1016/j.clpt.2005.04.006. Clin Pharmacol Ther. 2005. PMID: 16003286 Review. No abstract available.

5

Drug-metabolizing enzyme inhibition by ketoconazole does not reduce interindividual variability of CYP3A activity as measured by oral midazolam.

Chen M, Nafziger AN, Bertino JS Jr. Chen M, et al. Among authors: nafziger an. Drug Metab Dispos. 2006 Dec;34(12):2079-82. doi: 10.1124/dmd.106.011742. Epub 2006 Sep 22. Drug Metab Dispos. 2006. PMID: 16997909 Clinical Trial.

6

Utility and application of urine drug testing in chronic pain management with opioids.

Nafziger AN, Bertino JS Jr. Nafziger AN, et al. Clin J Pain. 2009 Jan;25(1):73-9. doi: 10.1097/AJP.0b013e31817e13cc. Clin J Pain. 2009. PMID: 19158549 Review.

7

Besifloxacin ophthalmic suspension for bacterial conjunctivitis.

Nafziger AN, Bertino JS Jr. Nafziger AN, et al. Drugs Today (Barc). 2009 Aug;45(8):577-88. Drugs Today (Barc). 2009. PMID: 19927224 Review.

8

Duration of pleconaril effect on cytochrome P450 3A activity in healthy adults using the oral biomarker midazolam.

Ma JD, Nafziger AN, Rhodes G, Liu S, Bertino JS Jr. Ma JD, et al. Among authors: nafziger an. Drug Metab Dispos. 2006 May;34(5):783-5. doi: 10.1124/dmd.105.007831. Epub 2006 Feb 7. Drug Metab Dispos. 2006. PMID: 16467135

9

Limited sampling models for oral midazolam: midazolam plasma concentrations, not the ratio of 1-hydroxymidazolam to midazolam plasma concentrations, accurately predicts AUC as a biomarker of CYP3A activity.

Lee LS, Bertino JS Jr, Nafziger AN. Lee LS, et al. Among authors: nafziger an. J Clin Pharmacol. 2006 Feb;46(2):229-34. doi: 10.1177/0091270005283466. J Clin Pharmacol. 2006. PMID: 16432275 Clinical Trial.

10

Desirudin dosing and monitoring in moderate renal impairment.

Nafziger AN, Bertino JS Jr. Nafziger AN, et al. J Clin Pharmacol. 2010 Jun;50(6):614-22. doi: 10.1177/0091270009350626. Epub 2009 Nov 13. J Clin Pharmacol. 2010. PMID: 19915180

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

121 results

Search Page